Cell and Gene Patient Engagement Therapy Summit on August 20-21, 2025 in Boston, United States

Join the 5th Cell and Gene Therapy Patient Engagement Summit, the only industry-tailored conference, focused on every aspect of the therapy lifecycle, to innovate a cross-functional approach to patient partnership.

Explore critical topics like quantifying patient engagement value and supporting shared decision making amongst others with industry leading companies like Bristol Myers Squibb, Sarepta Therapeutics and Ultragenyx Pharmaceuticals, to improve patient centricity, transparency and education.

URL:

Brochure: https://go.evvnt.com/3086594-2?pid=10008

Time: 8:55 AM - 4:00 PM

Prices:

2 Day Conference Pass - Drug Developers: USD 2599.00,

2 Day Conference Pass - Solution Providers: USD 3299.00

Speakers: Adam Clark, Director of Foundation Operations, Emily Whitehead Foundation, Amy Corrao, Senior Director, US and Worldwide Portfolio Strategy, Cell Therapy, Bristol Myers Squibb, Behtash Bahador, Director - Health Literacy, Center For Information and Study on Clinical Research Participation, Christine Schlegel Brown, Associate Director, Patient Partnership, Astellas Pharma, Cybele Gouverneur, Director, Global Patient Advocacy, BridgeBio Pharma, Inc., Desiree Wienand, National Director - Corporate Engagement, Lupus Foundation of America, Erin Frey, Senior Director, State Government Affairs, Ultragenyx Pharmaceutical Inc., Kathleen O’Sullivan-Fortin, Directors - Board, Treasurer and General Counsel, ALD Connect, Laura Bermingham, Program Director, SLC6A1 Connect, Marcelyne Joseney-Antoine, Clinical Operations and Hematology Asset Lead, Beam Therapeutics, Mary Rohrer, Director - Patient Recruitment and Retention, BridgeBio Pharma, Inc., Michael Sherman, Chief Executive Officer, Sherman Health Systems, Pat Furlong, Founding President and Chief Executive Officer, Parent Project Muscular Dystrophy, Rohita Sharma, Senior Director - Global Strategic Alliances, Patient Experience, Medical Affairs, Patient Insights, Solutions and Rare Diseases, Alexion Pharmaceuticals, Wendy Erler, Senior Vice President - Patient Affairs, Sarepta Therapeutic